Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||
|
Bluebird Bio
|
2024 | |||
Bluebird Bio Q4 2023 |
Bluebird Bio Q1 2024 |
Bluebird Bio Q2 2024 |
|
Mar. 26, 2024 | May 9, 2024 | Aug. 14, 2024 |
Bluebird Bio (BLUE) is a commercial stage biotechnology company specializing in genetic therapies, including Lyfgenia for Sickle Cell Disease.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BMY |
CLDX |
CDTX |
GILD |
GLYC |
ILMN |
IMGN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
RETA |
REGN |
RNA |
SAGE |
SYRS |
TSVT |
VSTM |
VRTX |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers